CY1106273T1 - Φαρμακευτικες συνθεσεις οι οποιες αποτελουνται απο ενα ή πepισσοτepα στepοειδη ενα ή πepισσοτepα συστατικα μιας τετραϋδροφολικης ενωσεως και βιταμινη β12 - Google Patents
Φαρμακευτικες συνθεσεις οι οποιες αποτελουνται απο ενα ή πepισσοτepα στepοειδη ενα ή πepισσοτepα συστατικα μιας τετραϋδροφολικης ενωσεως και βιταμινη β12Info
- Publication number
- CY1106273T1 CY1106273T1 CY20061101724T CY061101724T CY1106273T1 CY 1106273 T1 CY1106273 T1 CY 1106273T1 CY 20061101724 T CY20061101724 T CY 20061101724T CY 061101724 T CY061101724 T CY 061101724T CY 1106273 T1 CY1106273 T1 CY 1106273T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tetrahydrofolic
- pepissotepa
- acid
- tetrahydrofolic acid
- vitamin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical class N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 229930003779 Vitamin B12 Natural products 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 abstract 2
- 239000003433 contraceptive agent Substances 0.000 abstract 2
- 238000002657 hormone replacement therapy Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- 239000011715 vitamin B12 Substances 0.000 abstract 2
- 235000019163 vitamin B12 Nutrition 0.000 abstract 2
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 abstract 1
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 abstract 1
- VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 abstract 1
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 abstract 1
- AUFGTPPARQZWDO-YPMHNXCESA-N 10-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)N(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YPMHNXCESA-N 0.000 abstract 1
- YCWUVLPMLLBDCU-STQMWFEESA-N 5-formimidoyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=N)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YCWUVLPMLLBDCU-STQMWFEESA-N 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000005460 tetrahydrofolate Substances 0.000 abstract 1
- -1 tetrahydrofolate compound Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μία φαρμακευτική συσκευασία για να χρησιμοποιηθεί σε μία ορμονική αντισυλληπτική μέθοδο ή σε μία ορμονοθεραπεία υποκαταστάσεως σε θηλυκά θηλαστικά, η εν λόγω συσκευασία περιέχει τουλάχιστον 10 δοσολογικές μονάδες για χορήγηση από του στόματος οι οποίες περιέχουν τουλάχιστον 1 μg ενός ή περισσοτέρων στεροειδών της ομάδας των οιστρογόνων και των προγεσταγόνων, τουλάχιστον 0.1 mg ενός ή περισσοτέρων συστατικών μιας τετραϋδοφολικής ενώσεως η οποία επιλέγεται από τα : (6S)-τετραϋδροφολικό οξύ, 5-μεθυλο-(6S)-τετραϋδροφολικό οξύ, 5-φορμυλο-(6S)-τετραϋδροφολικό οξύ, 10-φορμυλο-(6R)-τετραϋδροφολικό οξύ, 5,10- μεθυλενο-(6R)-τετραϋδρο-φολικό οξύ, 5,10-μεθενυλο-(6R)-τετραϋδροφολικό οξύ, 5-φορμιμινο-(6S)-τετραϋδροφολικό οξύ, τα φαρμακευτικώς αποδεκτά άλατα αυτών των τετραϋδροφολικών οξέων και τα παράγωγα γλουταμυλίου αυτών των τετραϋδροφολικών οξέων και τουλάχιστον 0.1 mg βιταμίνης Β12. Άλλα σκέλη της εφευρέσεως αυτής σχετίζονται με μία ορμονική αντισυλληπτική μέθοδο και μία ορμονοθεραπεία υποκαταστάσεως οι οποίες περιλαμβάνουν τη χορήγηση δοσολογικών μονάδων σε ένα θηλυκό θηλαστικό που περιέχουν ένα ή περισσότερα στεροειδή, όπου οι δοσολογικές μονάδες περιέχουν επιπλέον τουλάχιστον 0.1 mg ενός ή περισσοτέρων συστατικών μιας τετραϋδοφολικής ενώσεως και τουλάχιστον 0.1 mg βιταμίνης Β12.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02075695 | 2002-02-21 | ||
EP02780174A EP1478373B1 (en) | 2002-02-21 | 2002-11-15 | Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12 |
PCT/NL2002/000741 WO2003070255A1 (en) | 2002-02-21 | 2002-11-15 | Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106273T1 true CY1106273T1 (el) | 2011-10-12 |
Family
ID=27741182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101724T CY1106273T1 (el) | 2002-02-21 | 2006-11-30 | Φαρμακευτικες συνθεσεις οι οποιες αποτελουνται απο ενα ή πepισσοτepα στepοειδη ενα ή πepισσοτepα συστατικα μιας τετραϋδροφολικης ενωσεως και βιταμινη β12 |
Country Status (29)
Country | Link |
---|---|
US (1) | US20050164977A1 (el) |
EP (1) | EP1478373B1 (el) |
JP (1) | JP5037779B2 (el) |
KR (1) | KR100936827B1 (el) |
CN (1) | CN1620302B (el) |
AT (1) | ATE341333T1 (el) |
AU (1) | AU2002343249B2 (el) |
BR (1) | BR0215613A (el) |
CA (1) | CA2476940C (el) |
CR (1) | CR7420A (el) |
CY (1) | CY1106273T1 (el) |
DE (1) | DE60215224T2 (el) |
DK (1) | DK1478373T3 (el) |
EA (1) | EA007599B1 (el) |
EC (1) | ECSP045305A (el) |
ES (1) | ES2274107T3 (el) |
HK (1) | HK1078780A1 (el) |
HU (1) | HUP0402674A3 (el) |
IL (2) | IL163579A0 (el) |
ME (1) | MEP37208A (el) |
MX (1) | MXPA04008185A (el) |
NO (1) | NO20043932L (el) |
NZ (1) | NZ534806A (el) |
PL (1) | PL209558B1 (el) |
PT (1) | PT1478373E (el) |
RS (1) | RS50909B (el) |
UA (1) | UA80965C2 (el) |
WO (1) | WO2003070255A1 (el) |
ZA (1) | ZA200407545B (el) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060293295A1 (en) * | 2005-05-13 | 2006-12-28 | Kai Strothmann | Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate |
AU2012227235B2 (en) * | 2005-05-13 | 2015-06-11 | Bayer Intellectual Property Gmbh | Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate |
DE102005023301B4 (de) * | 2005-05-13 | 2012-05-31 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
UY29527A1 (es) * | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
AU2013202756B2 (en) * | 2006-07-06 | 2015-06-04 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
MX2009000256A (es) * | 2006-07-06 | 2009-02-18 | Bayer Schering Pharma Ag | Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas. |
EP1891959A1 (de) * | 2006-08-14 | 2008-02-27 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
GB0715502D0 (en) * | 2007-08-08 | 2007-09-19 | Univ Manchester | Methods |
JP2011511823A (ja) * | 2008-02-13 | 2011-04-14 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | エストラジオール含有薬物の送達システム |
UY32836A (es) | 2009-08-12 | 2011-03-31 | Bayer Schering Pharma Ag | Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato |
EP2324832B2 (de) * | 2009-11-09 | 2016-11-30 | Biogena Naturprodukte GmbH & Co KG | Nahrungsergänzungsmittel bei Einnahme von hormonellen Kontrazeptiva |
WO2012164095A1 (en) | 2011-06-01 | 2012-12-06 | Estetra S.A. | Process for the production of estetrol intermediates |
SG195118A1 (en) | 2011-06-01 | 2013-12-30 | Estetra S A | Process for the production of estetrol intermediates |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
ES2925534T3 (es) * | 2011-11-05 | 2022-10-18 | South Alabama Medical Science Found | Métodos, formulaciones y kits para reponer rápidamente los niveles de folato en mujeres |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
MX369035B (es) * | 2013-12-12 | 2019-10-25 | Donesta Bioscience B V | Unidad de dosificacion solida de disolucion oral que contiene un componente de estetrol. |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
UA123098C2 (uk) | 2015-06-18 | 2021-02-17 | Естетра Спрл | Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент |
US10894014B2 (en) | 2015-06-18 | 2021-01-19 | Estetra Sprl | Orodispersible tablet containing Estetrol |
PE20231714A1 (es) | 2015-06-18 | 2023-10-23 | Estetra Sprl | Unidad de dosificacion orodispersable que contiene un componente estetrol |
SI3310346T1 (sl) | 2015-06-18 | 2021-07-30 | Estetra Sprl | Orodisperzibilna tableta, ki vsebuje estetrol |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027764A1 (en) * | 1996-01-31 | 1997-08-07 | South Alabama Medical Science Foundation | Food and vitamin preparations containing the natural isomer of reduced folates |
CA2261764A1 (en) * | 1996-07-30 | 1998-02-05 | Jeffrey B. Blumberg | Dietary supplements |
US6274564B1 (en) * | 1996-09-18 | 2001-08-14 | William J. Sarill | Compositions of cobalamin and related corrinoids, and uses thereof |
US6220453B1 (en) * | 1998-04-07 | 2001-04-24 | Fuji Photo Film Co., Ltd. | Blood filter unit |
AU3567699A (en) * | 1998-04-17 | 1999-11-08 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
AU4573899A (en) * | 1998-06-19 | 2000-01-05 | Beth Israel Deaconess Medical Center | Dietary supplement for post-menopausal women |
US6479545B1 (en) * | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
DE10022510A1 (de) * | 2000-05-10 | 2001-11-15 | Basf Ag | Zusammensetzungen enthaltend Folsäure und reduziertes Folat |
BG104880A (en) * | 2000-10-24 | 2002-04-30 | Иван ХРИСТОВ | Medicamentous preparation for multiple sclerosis treatment |
-
2002
- 2002-11-15 BR BR0215613-0A patent/BR0215613A/pt not_active IP Right Cessation
- 2002-11-15 EA EA200401014A patent/EA007599B1/ru not_active IP Right Cessation
- 2002-11-15 CN CN028282809A patent/CN1620302B/zh not_active Expired - Fee Related
- 2002-11-15 EP EP02780174A patent/EP1478373B1/en not_active Expired - Lifetime
- 2002-11-15 HU HU0402674A patent/HUP0402674A3/hu unknown
- 2002-11-15 AT AT02780174T patent/ATE341333T1/de active
- 2002-11-15 WO PCT/NL2002/000741 patent/WO2003070255A1/en active IP Right Grant
- 2002-11-15 IL IL16357902A patent/IL163579A0/xx active IP Right Grant
- 2002-11-15 PT PT02780174T patent/PT1478373E/pt unknown
- 2002-11-15 CA CA2476940A patent/CA2476940C/en not_active Expired - Fee Related
- 2002-11-15 US US10/505,555 patent/US20050164977A1/en not_active Abandoned
- 2002-11-15 DE DE60215224T patent/DE60215224T2/de not_active Expired - Lifetime
- 2002-11-15 DK DK02780174T patent/DK1478373T3/da active
- 2002-11-15 JP JP2003569211A patent/JP5037779B2/ja not_active Expired - Fee Related
- 2002-11-15 ES ES02780174T patent/ES2274107T3/es not_active Expired - Lifetime
- 2002-11-15 UA UA20040907578A patent/UA80965C2/uk unknown
- 2002-11-15 MX MXPA04008185A patent/MXPA04008185A/es active IP Right Grant
- 2002-11-15 AU AU2002343249A patent/AU2002343249B2/en not_active Ceased
- 2002-11-15 NZ NZ534806A patent/NZ534806A/en not_active IP Right Cessation
- 2002-11-15 ME MEP-372/08A patent/MEP37208A/xx unknown
- 2002-11-15 KR KR1020047012983A patent/KR100936827B1/ko not_active IP Right Cessation
- 2002-11-15 PL PL371441A patent/PL209558B1/pl not_active IP Right Cessation
- 2002-11-15 RS YUP-733/04A patent/RS50909B/sr unknown
-
2004
- 2004-08-17 IL IL163579A patent/IL163579A/en not_active IP Right Cessation
- 2004-08-20 CR CR7420A patent/CR7420A/es not_active Application Discontinuation
- 2004-09-20 NO NO20043932A patent/NO20043932L/no not_active Application Discontinuation
- 2004-09-20 ZA ZA200407545A patent/ZA200407545B/en unknown
- 2004-09-21 EC EC2004005305A patent/ECSP045305A/es unknown
-
2005
- 2005-11-25 HK HK05110751.3A patent/HK1078780A1/xx not_active IP Right Cessation
-
2006
- 2006-11-30 CY CY20061101724T patent/CY1106273T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106273T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες αποτελουνται απο ενα ή πepισσοτepα στepοειδη ενα ή πepισσοτepα συστατικα μιας τετραϋδροφολικης ενωσεως και βιταμινη β12 | |
AU2009238379B2 (en) | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems | |
TW474812B (en) | Pharmaceutical preparations for influencing the homocysteine level comprising tetrahydrofolates in natural stereoisomeric form | |
TW200500098A (en) | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery | |
RU98111617A (ru) | Применение тетрагидрофолатов естественной стереоизомерной формы при получении фармацевтической композиции, предназначенной для воздействия на уровень гомоцистеина, в частности для поддержания процесса реметилирования гомоцистеина | |
CO5060477A1 (es) | Forma de dosificacion de nefazodona | |
US20060216361A1 (en) | Compositions and methods for the treatment of osteoporosis and inflammatory joint disease | |
BRPI0713999A2 (pt) | produÇço farmacÊutica para contracepÇço e para reduÇço do risco de malformaÇÕes congÊnitas | |
de Rouw et al. | Mechanisms, management and prevention of pemetrexed-related toxicity | |
US20050113332A1 (en) | Compositions and methods for treating an arthritic condition | |
JP2004538262A5 (el) | ||
AU2001297789A1 (en) | Compositions and methods for treating an arthritic condition | |
NO950950L (no) | Farmasöytisk preparat | |
CY1106961T1 (el) | Χρηση παραγοντα μειωσης περιεκτικοτητας ομοκυστεϊνης πλασματος για τη μειωση του κινδυνου θρομβοεμβολικης παρενεργειας που προκαλειται απο ορμονες τυπου προγεστερονης | |
US20080153831A1 (en) | Isoflavone-containing compositions for the treatment of osteoporosis and inflammatory joint disease | |
ES1286975U (es) | Comprimido que contiene 25-OH vitamina D3 | |
IT1255969B (it) | Formulazioni di acido ursodesossicolico a rilascio controllato | |
AU2003219641A1 (en) | Analgesical oral composition with controlled release of an opioid | |
MY145885A (en) | Controlled release formulations for oral administration | |
JP2004002408A (ja) | 鼻炎用組成物 | |
MXPA98004683A (en) | The use of tetrahydrofolates in a natural stereoisomeric form for the production of an adequate pharmaceutical preparation to influence the homocysteine level, particularly to help in the homociste remedy |